orforglipron

Orforglipron is an investigational **oral, non-peptide small-molecule glucagon-like peptide 1 receptor agonist** being developed primarily by **Eli Lilly** after licensing from **Chugai Pharmaceutical**. It is designed for **once-daily oral dosing without food or water restrictions** and acts as a **partial, biased GLP-1 receptor agonist**, favoring cAMP signaling with relatively low β-arrestin recruitment. Across phase 1, phase 2, and publicly reported phase 3 studies, orforglipron has shown clinically meaningful reductions in **HbA1c** and **body weight** in **type 2 diabetes** and **obesity/overweight**, with a safety profile dominated by class-consistent **gastrointestinal adverse events** such as nausea, vomiting, diarrhea, constipation, and eructation. Its long half-life supports once-daily dosing, and it is positioned as a potential oral alternative to injectable GLP-1 receptor agonists and oral peptide semaglutide.

Brand names

Foundayo

Other names

orforglipron